IPROOV
iProov , the world leader in spoof-resistant, biometric authentication technology, today announced that its technology has been deployed to verify users signing up to NHS login across Android and iOS. Following an initial launch on Android, iProov’s technology is now available on the iOS version of the NHS App.
This enables users in England to create their NHS login remotely, securely and conveniently at a time when they need it most, removing the need for manual and in-person verifications. The NHS App allows for easy and fast access to essential services such as GP appointments, access to medical records and ordering repeat prescriptions.
iProov’s Flashmark facial verification technology is now used by users to create an NHS login through the NHS App. Once a user submits a photo of their identity document, such as a valid passport or driving licence, they will be prompted to position their face correctly on the screen. Following a short sequence of flashing colours, the user’s identification will be verified and they will be able to access all the information and services the NHS App has to offer, following completion of all other checks including matching a user to their medical record.
The iProov process verifies that an individual is a real person, the right person, and is authenticating themselves right now. This protects against the risk of identity theft while giving people quicker and more convenient access to vital services wherever they are. It also frees up valuable NHS resources and saves money, as NHS Digital now needs to process far fewer manual applications. More than a million people have now registered with NHS login, with a peak of over 60,000 new IDs verified during the first week of April. The combined iProov and NHS solution has proven its ability to cope with an unprecedented increase in demand.
Andrew Bud, Founder and CEO, iProov said: “The NHS login service is now a proven, secure, inclusive and effective way for citizens to verify and use their identity for health-related purposes. We have been very impressed by what the NHS Digital team has accomplished, by their agility and professionalism, and by the boldness of their vision.
“This is particularly important in the current climate in which demand is unprecedented and the need for convenient and robust remote identity verification is crucial. We are delighted to be playing our part.”
Melissa Ruscoe, Programme Head for NHS login, said: “iOS users are now able to benefit from faster automatic identity verification when creating their NHS login, giving them a single safe and secure way to access their digital healthcare services such as the NHS App.
“Over the past couple of months we have seen a surge in demand in people registering for an NHS login as they look to manage their health digitally.
“More automated tools like this will help us to improve the experience of our users, increase demand capacity and ensure nobody is waiting too long to complete identity verification checks to gain access to their digital healthcare services.”
In addition to NHS login, iProov’s unique patented technology is used to verify identities in the Home Office ‘EU Exit: ID Document Check’ app which enables European citizens to apply to the EU Settlement Scheme. iProov also provides governments, banks and other enterprises with Genuine Presence Assurance, including the US Department for Homeland Security, allowing them to authenticate users remotely on smartphones or other devices.
ENDS
About iProov
Founded in 2011, iProov is a world leader in spoof-resistant, biometric facial authentication technology. Its technology is used by banks and governments around the world for secure customer onboarding, logon and authentication, to ensure new and returning users are genuine, and to guard against fraudulent attempts to gain access to personal data. For more information, see www.iproov.com
.
About NHS login
NHS login is a service that has been created by the NHS for patients and the public. It provides a re-usable way for patients to access multiple digital health and social care services with a single login, which includes authentication for returning users.
NHS login can be used by the public to securely access their health and care information wherever they see the NHS login button. People can use NHS login to prove who they are safely and securely and, in most cases, without the need to visit their GP.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005254/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
